Clinical Significance of BRAF Gene Mutations in Patients with Non-small Cell Lung Cancer

V-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations are attractive molecular targets for cancer treatment. Detection of BRAF gene mutation and analyses in non-small cell lung cancer (NSCLC) are of great scientific interest. The study included 581 NSCLC patients (377 males, 204 female) un...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2011-12, Vol.31 (12), p.4619-4623
Main Authors: KOBAYASHI, Masashi, SONOBE, Makoto, TAKAHASHI, Tsuyoshi, YOSHIZAWA, Akihiko, ISHIKAWA, Masashi, KIKUCHI, Ryutaro, OKUBO, Kenichi, HUANG, Cheng-Long, DATE, Hiroshi
Format: Article
Language:English
Subjects:
Adenocarcinoma - genetics
Aged
Biological and medical sciences
Carcinoma, Non-Small-Cell Lung - genetics
Carcinoma, Squamous Cell - genetics
Codon
DNA Mutational Analysis
Exons
Female
Gene Expression Regulation, Neoplastic
Genes, erbB-2 - genetics
Genes, ras - genetics
Humans
Lung Neoplasms - genetics
Male
Medical sciences
Middle Aged
Mutation
Pneumology
Polymorphism, Single-Stranded Conformational
Proto-Oncogene Proteins B-raf - genetics
Tumors
Tumors of the respiratory system and mediastinum
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:V-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations are attractive molecular targets for cancer treatment. Detection of BRAF gene mutation and analyses in non-small cell lung cancer (NSCLC) are of great scientific interest. The study included 581 NSCLC patients (377 males, 204 female) undergoing pulmonary resection. BRAF gene mutations were screened using the PCR-SSCP method and were confirmed by direct DNA sequencing. Mutations of epidermal growth factor receptor (EGFR), v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 (ERBB2), and v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) gene were also analyzed. Five patients (0.8%) had BRAF mutations within exon 15. In 581 NSCLC patients, EGFR gene mutations within exons 18 to 21 were detected in 191 (32.8%) patients, KRAS codon 12 mutations in 56 (9.6%) patients, and ERBB2 codon 20 mutations in 11 (1.8%) patients. All mutations were mutually exclusive. The NSCLC patients with BRAF mutations were proved to be men who were heavy smokers. PCR-SSCP analysis of BRAF exon 15 in NSCLC patients without other gene mutations may be sufficient to identify candidates for treatment.
ISSN:0250-7005
1791-7530